SCHEMBL2897110

SCHEMBL2897110

O=C(C=Cc1cccc2ccccc12)N1CCC(=O)N(CCCN2CCCCC2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.52
KDM4E B2RXH2 2/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.44
HRH3 Q9Y5N1 5/20 0.42
MAPT P10636 2/20 0.40
ALDH1A1 P00352 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PARP1 P09874 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HPGD P15428 1/20 0.39
HTR2A P28223 2/20 0.38
HTR7 P34969 2/20 0.38
HTR6 P50406 2/20 0.38
GPR183 P32249 1/20 0.38
GCGR P47871 1/20 0.38
BCHE P06276 1/20 0.38
HDAC8 Q9BY41 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2897108 1.00 NPC1 (0.52) NPC1KDM4ERAB9ASMN1; SMN2HRH3
SCHEMBL2896739 0.84 MEN1 (0.54) KDM4ERAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL2896736 0.84 MEN1 (0.54) KDM4ERAB9ASMN1; SMN2MAPTALDH1A1
SCHEMBL2905093 0.83 GPR183 (0.42) NPC1RAB9AHRH3MAPTALDH1A1
SCHEMBL2905099 0.83 GPR183 (0.42) NPC1RAB9AHRH3MAPTALDH1A1
SCHEMBL2896867 0.80 MEN1 (0.48) HRH3ALDH1A1GPR183
SCHEMBL2896871 0.80 MEN1 (0.48) HRH3ALDH1A1GPR183
SCHEMBL4385602 0.78 NPC1 (0.61) NPC1KDM4ERAB9ASMN1; SMN2HRH3
SCHEMBL13636361 0.78 NPC1 (0.61) NPC1KDM4ERAB9ASMN1; SMN2HRH3
SCHEMBL2903152 0.77 LMNA (0.48) SMN1; SMN2MAPTALDH1A1L3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010506-B1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2010-08-04 EP disclosed
US-7632829-B2 Diazepan derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-15 US disclosed
EP-2010506-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-Roche AG (CH) 2009-01-07 EP disclosed
WO-2007122103-A1 DIAZEPAN DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-01 WO disclosed
US-20070249589-A1 Novel diazepan derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249589-A1 Novel diazepan derivatives CCR3, CCR1, CCR10 NPC1 1598/4885KDM4E 3080/4885RAB9A 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.